Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of AST-3424 in Treatment of Patients With Advanced Solid Tumors and Its Correlation With AKR1C3 Enzyme Expression

Next Previous
Trial Profile

Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of AST-3424 in Treatment of Patients With Advanced Solid Tumors and Its Correlation With AKR1C3 Enzyme Expression

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs OBI 3424 (Primary)
  • Indications Carcinoma; Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Liver cancer; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Prostate cancer; Renal cell carcinoma; Salivary gland cancer; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Ascentawits Pharmaceuticals

Most Recent Events

  • 25 Feb 2025 Status changed from recruiting to active, no longer recruiting.
  • 13 Oct 2024 According to an Ascentawits Pharmaceuticals Media Release, Professor Qin Shukui from Nanjing Tianyinshan Hospital, China Pharmaceutical University, one of the investigators of the study.
  • 13 Oct 2024 According to an Ascentawits Pharmaceuticals Media Release, interim results were at the 2024 annual meeting of the Chinese Society of Clinical Oncology (CSCO) on September 27.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top